PRA Health Sciences (PRAH) PT Raised to $93 at KeyBanc

KeyBanc raised its price target on PRA Health Sciences (NASDAQ: PRAH) to $93.00 (from $86.00) while maintaining a Overweight rating.

Analyst Donald Hooker came away from a meeting with management slightly more positive on the acquisition of Symphony Health along with momentum from the core CRO business. The analyst believes the equity should trade at a premium that reflects strong than expected trends in Symphony Health along with EBITDA growth in 2018/2019.

You May Also Be Interested In

• Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
• Aon Corp (AON) PT Lowered to $349 at Piper Sandler
• Designer Brands (DBI) PT Lowered to $6 at UBS